Editors
Transitions A.A.M. Bookman .......................... 1
Send Us Your Best E. Silverman ......................... 3
•
Evaluating the Real-world Benefits and Risks of Anti-Tumor Necrosis Factor Therapies A. Low, K. Hyrich 4
Rhubarb and Reliability — A Jane Austen View of Systemic Lupus Erythematosus D.A. Isenberg ............ 7

Review
The Risky Business of Studying Prognosis L.S.H. Lim, B.M. Feldman .......................... 9

Articles
Hospitalizations of Patients Treated with Anti-TNF-α Agents — A Retrospective Cohort Analysis D. Zisman, A. Haddad, S. Hashoul, et al .......................... 16
HCQ Use Is Associated with Lower Odds of Persistently Positive Antiphospholipid Antibodies and/or Lupus Anticoagulant in SLE A. Broder, C. Putteman .......................... 30
Longterm Effects of Endothelin Receptor Antagonism on Microvascular Damage Evaluated by Nailfold Capillaroscopic Analysis in SSc M. Cutolo, G. Zampogna, L. Vrems, V. Smith, C. Pizzorni, A. Sulli .......................... 40
Is Vasculopathy Associated with SSc More Severe in Men? S.T. Panopoulos, V-K. Bounia, P.P. Slikakis .......................... 46
Two-year Results of an Open Pilot Study of a 2-treatment Course with Rituximab in Patients with Early SSc with Diffuse Skin Involvement V. Smith, Y. Piette, J.T. Van Praet, S. Decuman, E. Deschepper, D. Elewaut, F. De Keyser .......................... 52

Consensus Statements for the Use of Administrative Health Data in Rheumatic Disease Research and Surveillance S. Bernatsky, L. Lix, S. O’Donnell, D. Lacaille, and the CANRAD Network .......................... 66

Pediatric Rheumatology
Safety and Efficacy of Infliximab and Adalimumab for Refractory Uveitis in JIA: 1-year Followup Data from the Italian Registry M.E. Zannin, C. Biolo, V.M. Gerlioni, et al .......................... 74
MTX and Injectable TNF-α Inhibitor Adherence and Persistence in Children with Rheumatic Diseases S. Ringold, S. Grant, C. Girdish, C.A. Wallace, S.D. Sullivan .......................... 80

Images in Rheumatology
Polyarteritis Nodosa A.P. Diamantopoulos, P. Pettersen .......................... 87

Correspondence
The Optimal Tool for Assessment of Organ Damage in APS M. Barbhaiya, D. Erkan .......................... 89
Reply P.G. Vlachoyiannopoulos .......................... 90
Right Ventricular Function in Systemic Sclerosis-associated PAH M. Koestenberger, W. Ravekes .......................... 90
Reply S.C. Mathai, P.M. Hassan .......................... 91
Is “F Fluorodeoxyglucose PET Useful to Assess Activity of Myositis? N. Pipitone, A. Versari, C. Salvarani .......................... 91
Reply T. Owada, R. Maezawa, K. Kurasawa .......................... 92
Low Prevalence of Anti-DFS70/LEDGF Antibodies in Patients with Dermatomyositis and Other Systemic Autoimmune Rheumatic Diseases Y. Muro, K. Sugiura, R. Nakashima, T. Mimori, M. Akiyama .......................... 92
Reply M. Mahler .......................... 94
Myopericarditis and Giant Cell Arteritis in the Elderly J.R. Nair, R. Karumanchery .......................... 95
Reply B. Granel, A. Daumas, P. Rossi, A. Jacquier .......................... 96

Contents continued opposite inside back cover
HLA-B*5801 Should Be Used to Screen for Risk of Stevens-Johnson Syndrome in Family Members of Han Chinese Patients Commencing Allopurinol Therapy  

Skin Perfusion of Fingers Shows a Negative Correlation with Capillaroscopic Damage in Patients with SSC  
E. Rosato, A. Giovannetti, S. Pisarri, F. Salsano  

Hepatitis E: Are Rheumatic Patients at Risk?  
C.H. Roux, R. Anty, S. Patouraux, L. Euller-Ziegler  

Refractory Relapsing Polychondritis Treated with Serial Success with IL-6R Blockade  
Z.S. Wallace, J.H. Stone  

Renal Lymphoma: Unusual Lymphoproliferative Manifestation of Sjögren’s Syndrome  
S. Patel, N. Kramer, A.J. Cohen, E.D. Rosenstein  

Achilles Tendinopathy After Treatment with Ophthalmic Moxifloxacin  
H. Gladue, M.J. Kaplan  

Eosinophilic Fascitis in Siblings  
C. Sullivan, R. Coughlan  

Scleroderma. From Pathogenesis to Comprehensive Management  

Safety and Efficacy of Infliximab and Adalimumab for Refractory Uveitis in Juvenile Idiopathic Arthritis: 1-year Followup Data from the Italian Registry  
M.E. Zannin, C. Birolo, V.M. Gerloni, et al  

Meetings in Rheumatology  

Downloaded from www.jrheum.org on November 15, 2017 - Published by The Journal of Rheumatology